600829.SH
人民同泰
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.22
−4.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.5B | 10.4B | 10.0B | 10.4B | 9.6B |
| Cost of Revenue | 9.7B | 9.5B | 9.2B | 9.4B | 8.7B |
| Gross Profit | 874.2M | 854.1M | 867.4M | 996.4M | 917.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 97.3M | 94.0M | 102.3M | 94.5M | 99.8M |
| Selling & Marketing Expense | 443.1M | 442.0M | 412.8M | 434.8M | 416.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 605.6M | 598.1M | 574.4M | 582.2M | 586.3M |
| Cost and Expenses | 10.3B | 10.1B | 9.8B | 10.0B | 9.3B |
| Operating Income (EBIT) | 202.7M | 197.4M | 288.9M | 399.4M | 347.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 193.3M | 189.5M | 289.1M | 393.4M | 345.6M |
| Income Tax Expense | 56.9M | 55.7M | 75.8M | 101.1M | 81.0M |
| Bottom Line | |||||
| Net Income | 136.5M | 133.8M | 213.3M | 292.2M | 264.5M |
| Earnings from Cont. Ops | 136.5M | 133.8M | 213.3M | 292.2M | 264.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 136.5M | 133.8M | 213.3M | 292.2M | 264.5M |
| Per Share | |||||
| Basic EPS | CN¥0.24 | CN¥0.23 | CN¥0.37 | CN¥0.50 | CN¥0.46 |
| Diluted EPS | CN¥0.24 | CN¥0.23 | CN¥0.37 | CN¥0.50 | CN¥0.46 |
| Revenue Per Share | CN¥18.17 | CN¥17.90 | CN¥17.33 | CN¥17.92 | CN¥16.63 |
| Shares | |||||
| Basic Shares Outstanding | 579.7M | 579.9M | 579.9M | 579.9M | 579.9M |
| Diluted Shares Outstanding | 579.7M | 579.9M | 579.9M | 579.9M | 579.9M |
| Profitability Metrics | |||||
| EBITDA | — | 219.8M | 312.8M | 425.4M | 372.8M |
| D&A | — | 22.4M | 23.9M | 26.0M | 25.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026